Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment
NCT00529581 is registered in ClinicalTrials.gov with Cognition Pharmaceuticals, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment
- Lead sponsor
- Cognition Pharmaceuticals, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- April 30, 2008
- Enrollment
- 150 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.